DelveInsight’s “Post Menopausal Osteoporosis Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Post Menopausal Osteoporosis, historical and forecasted epidemiology as well as the Post Menopausal Osteoporosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of Post Menopausal Osteoporosis Report Facts:
The total diagnosed prevalent population of osteoporosis in the seven major markets was found to be 28,097,783 cases in 2017. While, the total diagnosed prevalent population of osteoporosis in the United States was found to be 6,380,754 cases in 2017, which is expected to increase by 2030.
Tian et al. conducted a study titled “Prevalence of osteoporosis and related lifestyle and metabolic factors of postmenopausal women and elderly men” wherein, the reported prevalence of osteoporosis in women was 9% in the United Kingdom, 15% in France and Germany, 16% in USA, and 38% in Japan. The prevalence of osteoporosis in the whole participants was 9.65% for postmenopausal women and 8.08% for elderly men.
In the EU5 countries the total diagnosed prevalent population of osteoporosis was found to be maximum in Germany with 4,309,667 cases, followed by Italy with 3,840,703 cases in 2017. While, France had the lowest number of diagnosed prevalent cases of osteoporosis with 2,786,944 cases in 2017.
A poster presented by the American Association of Clinical Endocrinologists stated that women with hip fracture have an increased mortality of 12% to 20% during the subsequent two years. More than 50% of hip fracture survivors are unable to return to independent living. More than 2 million osteoporosis-related fractures occur each year in the United States, and more than 70% of these occur in women. More than 20% of postmenopausal women have prevalent vertebral fractures.
According to a study conducted by Sessa titled “Clinical guidelines for the prevention and treatment of osteoporosis from the Italian Society for Orthopaedics and Traumatology: preface” stated that in Italy, osteoporosis potentially affects about 5,000,000 people, of whom 80% are women of post-menopausal age.
Get Free Sample copy @ https://www.delveinsight.com/sample-request/post-menopausal-osteoporosis-market
Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis is of two different types, primary and secondary.
Primary Osteoporosis is linked to the normal aging process. It can be further divided into “primary type I” and “primary type II” osteoporosis. Type I is generally referred to as postmenopausal osteoporosis (PMO), as it is more commonly seen among women (six times more frequent) who have gone through menopause, resulting in a drop in levels of estrogen. Primary type I osteoporosis occurs in women about 10 to 15 years after menopause, usually between the ages of 50 and 70. Type II osteoporosis (also known as senile), commonly caused by a long term calcium deficiency. Women are twice as more likely than men to suffer from
Type II osteoporosis. Secondary Osteoporosis develops when certain medical conditions and medications increase bone remodeling leading to disruption of bone reformation.
Some of Post Menopausal Osteoporosis Companies:
Eli Lilly and Company,
Ligand Pharmaceuticals Incorporated.
Merck & Co., Inc
Outlook Therapeutics, Inc
And Many Others
And Many Others
Request for Detailed Post Menopausal Osteoporosis Therapies @ https://www.delveinsight.com/sample-request/post-menopausal-osteoporosis-market
Table of Contents:
1. Key Insights
2. Executive Summary of Post Menopausal Osteoporosis
3. Competitive Intelligence Analysis for Post Menopausal Osteoporosis
4. Post Menopausal Osteoporosis: Market Overview at a Glance
5. Post Menopausal Osteoporosis: Disease Background and Overview
6. Patient Journey
7. Post Menopausal Osteoporosis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Post Menopausal Osteoporosis Treatment
11. Marketed Products
12. Emerging Therapies
13. Post Menopausal Osteoporosis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Post Menopausal Osteoporosis
17. KOL Views
18. Market Drivers
19. Market Barriers
21. DelveInsight Capabilities
23. About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States